Hemostasis Diagnostics Market

Hemostasis Diagnostics Market (Product Type - Laboratory Systems, Consumables, and Point-of-Care Testing Systems; Test Type - Prothrombin Test Time (PT), Activated Partial Thromboplastin Time (APTT), Fibrinogen Degradation Products (FDP), Activated Clotting Time, Platelet Aggregation Test, and D Dimer; End Users - Hospital/Clinics, Independent Diagnostic Laboratories, and Home Care Settings) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

  • According to Transparency Market Research’s latest report on the global hemostasis diagnostics market for the historical period 2017–2018 and forecast period 2019–2027, rise in prevalence of blood clotting disorders, high prevalence of cardiovascular diseases are projected to drive the global hemostasis diagnostics market during the forecast period
  • According to the report, the global hemostasis diagnostics market was valued at US$ 2.3 Bn in 2018 and is anticipated to expand at a CAGR of 8.5% from 2019 to 2027

Request a sample to get extensive insights into the Hemostasis Diagnostics Market

Rise in Prevalence of Blood Clotting Disorders and High Prevalence of Cardiovascular Diseases: Key Drivers

  • Bleeding easily when bruised is called abnormal bleeding. It can be due to blood clotting disorder, when the body is unable to produce clotting factors to stop bleeding. Hemophilia A and B, along with factor II, V, VII, X, or XII deficiencies are blood disorders identified with abnormal bleeding issues or blood coagulating issues. Over 440,000 people are suffering from hemophilia globally; of these 75% people are affected in less developed and developing countries
  • In 2018, it was estimated that over 13,600 people in the United States had been diagnosed with hemophilia A, while around 4,100 had been diagnosed with hemophilia B. Hemophilia is more common among males than females, with around 90% of hemophilia A cases worldwide occurring among males.
  • Prevalence of numerous diseases such as cancer, diabetes, and neurological disorders has increased due to rise in geriatric population and changing lifestyle in developing economies. Cardiovascular disease is one of the major factor in this. According to the WHO, cardiovascular diseases account for 17.5 million deaths across the world, which is about 31% of all the deaths globally. Deep vein thrombosis is one of the cardiovascular complications, wherein blood clots are formed within the deep vein, commonly in the legs. According to the CDC, about 900,000 people could be affected each year in the U.S. It is suggested that around 60,000 to 100,000 people in the U.S. die due to this disease.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Advancement in Technology Leading to Easy Usage Boost Market Growth

  • Hemostasis diagnostics devices have come a long way from quantifying optical density of clot in a cuvette to detection of clotting factors. Advancements in hemostasis technology has led to development of wide range of products that have enabled clinicians to provide proper emergency assistance to patients.
  • The concept of automation has extended to hemostasis diagnostics as well, which is less labor intensive, rapid, and easy-to-use. Current technologies include automation of blood coagulation analyzers, flow cytometers, microarrays, and PCR. Combination of these technologies has increased the yield and productivity.
  • This technological revolution in hemostasis diagnostics is expected to propel the market from 2019 to 2027.

High Cost of Automated Instruments to Hamper Market

  • Advancements in technology in hemostasis diagnostics instruments carry a heavy price tag. Laboratories cannot afford high cost instruments. Therefore, there is a need for basic coagulation instruments, which are cost effective and easy-to-use.
  • At a list price of US$ 49,000, the Accuri C6 is in the lower-middle range of benchtop flow cytometer instruments, which start at $14,000 for the closed-architecture Muse Cell Analyzer from EMD Millipore. Most instruments cost $75,000 to $100,000 for a two-laser, four- to six-color instrument.
  • High instrument cost can increase testing expenditure, which can restrain the global hemostasis diagnostics market during the forecast period

Global Hemostasis Diagnostics Market: Competitive Landscape

  • This report profiles major players in the global hemostasis diagnostics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global hemostasis diagnostics market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global hemostasis diagnostics market are
    • Abbott Laboratories
    • Thermo Fisher Scientific, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Nihon Kohden Corporation
    • Sysmex Corporation
    • Siemens Healthineers
    • Instrumentation Laboratory
    • Danaher Corporation (Beckman Coulter)
    • Grifols
    • S.A. among others

Global Hemostasis diagnostics market: Key Developments

Key players in the global hemostasis diagnostics market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global hemostasis diagnostics market. A few expansion strategies adopted by players operating in the global hemostasis diagnostics market are:

  • In July 2020, Sysmex Corporation launched of new products in the hemostasis field: the Automated Blood Coagulation Analyzers CN-6500/CN-3500. These new offerings from Sysmex come with a measuring unit using the chemiluminescence enzyme immunoassay methodology (CLEIA), which we cultivated in our Automated Immunoassay Systems HISCL-5000/HISCL-800 (HISCL), on top of the unique features of the Automated Blood Coagulation Analyzers CN-6000/CN-3000, making it possible to measure blood coagulation testing parameters, including molecular markers for blood coagulation with a single device.
  • In May 2018, HORIBA UK Ltd launched new Yumizen G range of instruments and reagents for Haemostasis solutions.
  • In April 2017, Starch Medical Inc. expanded its hemostasis portfolio with launch of SuperClot Hemostat in Europe.

The report on the global hemostasis diagnostics market discussed individual strategies, followed by company profiles of manufacturers of hemostasis diagnostics devices. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global hemostasis diagnostics market.

Hemostasis Diagnostics Market to Observe Growth in High Prevalence of Coagulation Disorders

Coagulation disorders are issues with the body’s capacity to clot blood. These conditions may result in hemorrhage or thrombosis. Coagulatory disorders can be caused by a variety of factors. These conditions may be developed or inherited. Platelet dysfunction, von Willebrand disease, and hemophilia are some of the most common coagulation disorders that can trigger bleeding. In addition to that, disseminated intravascular coagulation, deficiency of Vitamin K, and other clotting factor defects are other causes of coagulation disorders that may lead to bleeding. These factors are likely to work in favor of the global hemostasis diagnostics market in near future. Hemophilia A is four times more common than hemophilia B, as per the National Hemophilia Foundation. In the United States, there are about 20,000 people suffering from hemophilia.

Rapid Technological Progress to Create Ample Opportunities for the Market

Technology progresses at a breakneck rate and it is likely to play an important role in the expansion of the global hemostasis diagnostics market in the years to come. Blood coagulation control has become increasingly important in recent years for assessing bleeding risk in comprehensive surgical procedures and dialysis, diagnosing hemorrhage causes, and designing anticoagulant medications. It is also utilized for determining the effectiveness of hemostatic therapies. From calculating the optical density of a clot in a cuvette to identifying factors of clotting, hemostasis diagnostics have come a long way. Platelet function analyzers, functional assays of particular coagulation proteins, molecular typing immunologic assays, chromogenic assays, and flow cytometry, and are examples of these techniques. These technical developments have resulted in improved sensitivity, accuracy, productivity, and capability, and eventually it leads to better patient clinical care.

There are two types of bleeding disorders: acquired and hereditary. Inherited bleeding disorders are caused by a lack of coagulation factors and are caused by a genetic predisposition. Circumstances that can occur at any point of time during a person's lifespan can induce acquired bleeding disorders. Hereditary bleeding disorders are caused by a lack or deficiency of particular clotting proteins, which function as procoagulants in the clotting cascade by precise interactions. Such factors are estimated to benefit global hemostasis diagnostics market in near future.

Global Hemostasis Diagnostics Market - Segmentation

Attribute Detail
Product Type
  • Laboratory Systems
  • Consumables
  • Point-of-Care Testing Systems
Product Type
  • Prothrombin Test Time (PT)
  • Activated partial thromboplastin time (APTT)
  • Fibrinogen degradation products (FDP)
  • Activated Clotting Time
  • Platelet Aggregation Test
  • D Dimer
  • Others
End-user
  • Hospital/Clinics
  • Independent Diagnostic Laboratories
  • Home Care Settings
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of hemostasis diagnostics market?

The global hemostasis diagnostics market was worth US$ 2.3 Bn and is projected to reach a value of US$ 4.7 Bn by the end of 2027

What is the anticipated CAGR of the hemostasis diagnostics market in the forecast period?

Hemostasis diagnostics market is anticipated to grow at a CAGR of 8.5% during the forecast period

Which region is expected to project the highest market share in the global hemostasis diagnostics market?

North America accounted for a major share of the global hemostasis diagnostics market

What are the key driving factors for the growth of the hemostasis diagnostics market?

Hemostasis Diagnostics Market is driven by rise in prevalence of blood clotting disorders and high prevalence of cardiovascular diseases

Who are the key players in the global hemostasis diagnostics market?

Key players in the global hemostasis diagnostics market include Abbott Laboratories, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Nihon Kohden Corporation, Sysmex Corporation, Siemens Healthineers, Instrumentation Laboratory, Danaher Corporation (Beckman Coulter), and Grifols, S.A.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Hemostasis Diagnostics Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Type Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Hemostasis Diagnostics Market Analysis and Forecast, 2017-2027

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Coagulation Disorders & Coagulation Pathways: Overview

        5.2. Epidemiology: Coagulation Disorders

        5.3. Regulatory Framework

        5.4. Reimbursement Scenario

        5.5. Hemostasis Diagnostics Market: Pricing Analysis

        5.6. Hemostasis Diagnostics Market: Value Chain Analysis

        5.7. Hemostasis Diagnostics Market: Porter’s Five Forces Analysis

    6. Global Hemostasis Diagnostics Market Analysis and Forecast, by Product Type

        6.1. Introduction & Definition

            6.1.1. Key Findings / Developments

        6.2. Global Hemostasis Diagnostics Market Value Forecast, by Product Type, 2017-2027

            6.2.1. Laboratory Systems

                6.2.1.1. Automated Systems

                6.2.1.2. Semi-automated Systems

                6.2.1.3. Manual Systems

            6.2.2. Consumables

            6.2.3. Point-of-Care Testing Systems

        6.3. Global Hemostasis Diagnostics Market Attractiveness, by Product Type

    7. Global Hemostasis Diagnostics Market Analysis and Forecast, by Test Type

        7.1. Introduction & Definition

            7.1.1. Key Findings / Developments

        7.2. Global Hemostasis Diagnostics Market Value Forecast, by Test Type, 2017-2027

            7.2.1. Prothrombin Test Time (PT)

            7.2.2. Activated partial thromboplastin time (APTT)

            7.2.3. Fibrinogen degradation products (FDP)

            7.2.4. Activated Clotting Time

            7.2.5. Platelet Aggregation Test

            7.2.6. D Dimer

            7.2.7. Others

        7.3. Global Hemostasis Diagnostics Market Attractiveness, by Test Type

    8. Global Hemostasis Diagnostics Market Analysis and Forecast, by End-user

        8.1. Introduction & Definition

            8.1.1. Key Findings / Developments

        8.2. Global Hemostasis Diagnostics Market Value Forecast, by End-user, 2017-2027

            8.2.1. Hospital/Clinics

            8.2.2. Independent Diagnostic Laboratories

            8.2.3. Home Care Settings

            8.2.4. Others

        8.3. Global Hemostasis Diagnostics Market Attractiveness, by End-user

    9. Global Hemostasis Diagnostics Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Global Hemostasis Diagnostics Market Value Forecast, by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. North America Hemostasis Diagnostics Market Attractiveness, by Region

    10. North America Hemostasis Diagnostics Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. North America Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Product Type, 2017-2027

            10.2.1. Laboratory Systems

                10.2.1.1. Automated Systems

                10.2.1.2. Semi-automated Systems

                10.2.1.3. Manual Systems

            10.2.2. Consumables

            10.2.3. Point-of-Care Testing Systems

        10.3. North America Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2027

            10.3.1. Prothrombin Test Time (PT)

            10.3.2. Activated partial thromboplastin time (APTT)

            10.3.3. Fibrinogen degradation products (FDP)

            10.3.4. Activated Clotting Time

            10.3.5. Platelet Aggregation Test

            10.3.6. D Dimer

            10.3.7. Others

        10.4. North America Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2027

            10.4.1. Hospital/Clinics

            10.4.2. Independent Diagnostic Laboratories

            10.4.3. Home Care Settings

            10.4.4. Others

        10.5. North America Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017-2027

            10.5.1. U.S.

            10.5.2. Canada

        10.6. North America Hemostasis Diagnostics Market Attractiveness Analysis

            10.6.1. By Product Type

            10.6.2. By Test Type

            10.6.3. By End-user

            10.6.4. By Country

    11. Europe Hemostasis Diagnostics Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Europe Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Product Type, 2017-2027

            11.2.1. Laboratory Systems

                11.2.1.1. Automated Systems

                11.2.1.2. Semi-automated Systems

                11.2.1.3. Manual Systems

            11.2.2. Consumables

            11.2.3. Point-of-Care Testing Systems

        11.3. Europe Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2027

            11.3.1. Prothrombin Test Time (PT)

            11.3.2. Activated partial thromboplastin time (APTT)

            11.3.3. Fibrinogen degradation products (FDP)

            11.3.4. Activated Clotting Time

            11.3.5. Platelet Aggregation Test

            11.3.6. D Dimer

            11.3.7. Others

        11.4. Europe Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2027

            11.4.1. Hospital/Clinics

            11.4.2. Independent Diagnostic Laboratories

            11.4.3. Home Care Settings

            11.4.4. Others

        11.5. Europe Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Spain

            11.5.5. Italy

            11.5.6. Rest of Europe

        11.6. Europe Hemostasis Diagnostics Market Attractiveness Analysis

            11.6.1. By Product Type

            11.6.2. By Test Type

            11.6.3. By End-user

            11.6.4. By Country/Sub-region

    12. Asia Pacific Hemostasis Diagnostics Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Asia Pacific Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Product Type, 2017-2027

            12.2.1. Laboratory Systems

                12.2.1.1. Automated Systems

                12.2.1.2. Semi-automated Systems

                12.2.1.3. Manual Systems

            12.2.2. Consumables

            12.2.3. Point-of-Care Testing Systems

        12.3. Asia Pacific Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2027

            12.3.1. Prothrombin Test Time (PT)

            12.3.2. Activated partial thromboplastin time (APTT)

            12.3.3. Fibrinogen degradation products (FDP)

            12.3.4. Activated Clotting Time

            12.3.5. Platelet Aggregation Test

            12.3.6. D Dimer

            12.3.7. Others

        12.4. Asia Pacific Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2027

            12.4.1. Hospital/Clinics

            12.4.2. Independent Diagnostic Laboratories

            12.4.3. Home Care Settings

            12.4.4. Others

        12.5. Asia Pacific Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Asia Pacific Hemostasis Diagnostics Market Attractiveness Analysis

            12.6.1. By Product Type

            12.6.2. By Test Type

            12.6.3. By End-user

            12.6.4. By Country/Sub-region

    13. Latin America Hemostasis Diagnostics Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Latin America Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Product Type, 2017-2027

            13.2.1. Laboratory Systems

                13.2.1.1. Automated Systems

                13.2.1.2. Semi-automated Systems

                13.2.1.3. Manual Systems

            13.2.2. Consumables

            13.2.3. Point-of-Care Testing Systems

        13.3. Latin America Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2027

            13.3.1. Prothrombin Test Time (PT)

            13.3.2. Activated partial thromboplastin time (APTT)

            13.3.3. Fibrinogen degradation products (FDP)

            13.3.4. Activated Clotting Time

            13.3.5. Platelet Aggregation Test

            13.3.6. D Dimer

            13.3.7. Others

        13.4. Latin America Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2027

            13.4.1. Hospital/Clinics

            13.4.2. Independent Diagnostic Laboratories

            13.4.3. Home Care Settings

            13.4.4. Others

        13.5. Latin America Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America Latin America

        13.6. Latin America Hemostasis Diagnostics Market Attractiveness Analysis

            13.6.1. By Product Type

            13.6.2. By Test Type

            13.6.3. By End-user

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Hemostasis Diagnostics Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Middle East & Africa Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Product Type, 2017-2027

            14.2.1. Laboratory Systems

                14.2.1.1. Automated Systems

                14.2.1.2. Semi-automated Systems

                14.2.1.3. Manual Systems

            14.2.2. Consumables

            14.2.3. Point-of-Care Testing Systems

        14.3. Middle East & Africa Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2027

            14.3.1. Prothrombin Test Time (PT)

            14.3.2. Activated partial thromboplastin time (APTT)

            14.3.3. Fibrinogen degradation products (FDP)

            14.3.4. Activated Clotting Time

            14.3.5. Platelet Aggregation Test

            14.3.6. D Dimer

            14.3.7. Others

        14.4. Middle East & Africa Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2027

            14.4.1. Hospital/Clinics

            14.4.2. Independent Diagnostic Laboratories

            14.4.3. Home Care Settings

            14.4.4. Others

        14.5. Middle East & Africa Hemostasis Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Middle East & Africa Hemostasis Diagnostics Market Attractiveness Analysis

            14.6.1. By Product Type

            14.6.2. By Test Type

            14.6.3. By End-user

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competition Matrix (by Tier and Size of companies)

        15.2. Market Share / Position Analysis, by Company, 2018

        15.3. Competitive Business Strategies

        15.4. Company Profiles

            15.4.1. Abbott Laboratories, Inc.

                15.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.1.2. Financial Analysis

                15.4.1.3. Growth Strategies

                15.4.1.4. SWOT Analysis

            15.4.2. Thermo Fisher Scientific, Inc

                15.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.2.2. Financial Analysis

                15.4.2.3. Growth Strategies

                15.4.2.4. SWOT Analysis

            15.4.3. F. Hoffmann-La Roche Ltd

                15.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.3.2. Financial Analysis

                15.4.3.3. Growth Strategies

                15.4.3.4. SWOT Analysis

            15.4.4. Nihon Kohden Corporation

                15.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.4.2. Financial Analysis

                15.4.4.3. Growth Strategies

                15.4.4.4. SWOT Analysis

            15.4.5. Sysmex Corporation

                15.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.5.2. Financial Analysis

                15.4.5.3. Growth Strategies

                15.4.5.4. SWOT Analysis

            15.4.6. Siemens Healthineers

                15.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.6.2. Financial Analysis

                15.4.6.3. Growth Strategies

                15.4.6.4. SWOT Analysis

            15.4.7. Instrumentation Laboratory

                15.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.7.2. Financial Analysis

                15.4.7.3. Growth Strategies

                15.4.7.4. SWOT Analysis

            15.4.8. Danaher Corporation (Beckman Coulter)

                15.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.8.2. Financial Analysis

                15.4.8.3. Growth Strategies

                15.4.8.4. SWOT Analysis

            15.4.9. Grifols, S.A.

                15.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.4.9.2. Growth Strategies

                15.4.9.3. SWOT Analysis

    List of Table

    Table 01: Global Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Product, 2019-2027

    Table 02: Global Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2017-2027

    Table 03: Global Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2017-2027

    Table 04: Global Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Region, 2019-2027

    Table 05: North America Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Product, 2019-2027

    Table 06: North America Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2019-2027

    Table 07: North America Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2019-2027

    Table 08: North America Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Country, 2019-2027

    Table 09: Europe Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Product, 2019-2027

    Table 10: Europe Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2019-2027

    Table 11: Europe Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2019-2027

    Table 12: Europe Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Country, 2019-2027

    Table 13: Asia Pacific Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Product, 2019-2027

    Table 14: Asia Pacific Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2019-2027

    Table 15: Asia Pacific Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2019-2027

    Table 16: Asia Pacific Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Country, 2019-2027

    Table 17: Latin America Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Product, 2017-2027

    Table 18: Latin America Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2017-2027

    Table 19: Latin America Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2019-2027

    Table 20: Latin America Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

    Table 21: Middle East & Africa Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Product, 2017-2027

    Table 22: Middle East & Africa Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2017-2027

    Table 23: Middle East & Africa Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2019-2027

    Table 24: Middle East & Africa Hemostasis Diagnostics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

    List of Figure

    Figure 01: Hemostasis Diagnostics Market Snapshot

    Figure 02: Global Hemostasis Diagnostics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2027

    Figure 03: Market Value Share By Product (2018)

    Figure 04: Market Value Share By End-user (2018)

    Figure 05: Market Value Share By Region(2018)

    Figure 06: Global Hemostasis Diagnostics Market Value Share Analysis, by Product, 2018 and 2027

    Figure 07: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Laboratory Systems, 2017-2027

    Figure 08: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Consumables, 2017-2027

    Figure 09: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Point-of-care Testing Systems, 2017-2027

    Figure 10: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Automated Systems, 2017-2027

    Figure 11: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Semi-automated Systems, 2017-2027

    Figure 12: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Manual Systems, 2017-2027

    Figure 13: Global Hemostasis Diagnostics Market Attractiveness Analysis, by Product

    Figure 14: Global Hemostasis Diagnostics Market Value Share Analysis, by Test Type, 2018 and 2027

    Figure 15: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Prothrombin Time (PT), 2017-2027

    Figure 16: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by APTT, 2017-2027

    Figure 17: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Fibrinogen Degradation Products (FDP), 2017-2027

    Figure 18: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Activated Clotting Time, 2017-2027

    Figure 19: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Platelet Aggregation Test, 2017-2027

    Figure 20: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by D Dimer, 2017-2027

    Figure 21: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027

    Figure 22: Global Hemostasis Diagnostics Market Attractiveness Analysis, by Test Type

    Figure 23: Global Hemostasis Diagnostics Market Value Share Analysis, by End-user, 2018 and 2027

    Figure 24: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital & Clinics, 2017-2027

    Figure 25: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Independent Diagnostic Laboratories, 2017-2027

    Figure 26: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Home Care Settings, 2017-2027

    Figure 27: Global Hemostasis Diagnostics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027

    Figure 28: Global Hemostasis Diagnostics Market Attractiveness Analysis, by End-user

    Figure 29: Global Hemostasis Diagnostics Market Value Share Analysis, by Region, 2018 and 2027

    Figure 30: Global Hemostasis Diagnostics Market Attractiveness Analysis, by Region

    Figure 31: North America Hemostasis Diagnostics Market Size (US$ Mn) Forecast, 2019-2027

    Figure 32: North America Hemostasis Diagnostics Market Attractiveness Analysis, by Country

    Figure 33: North America Hemostasis Diagnostics Market Value Share Analysis, by Product, 2018 and 2027

    Figure 34: North America Hemostasis Diagnostics Market Value Share Analysis, by Test Type, 2018 and 2027

    Figure 35: North America Hemostasis Diagnostics Market Value Share Analysis, by End-user, 2018 and 2027

    Figure 36: North America Hemostasis Diagnostics Market Value Share Analysis, by Country, 2018 and 2027

    Figure 37: North America Hemostasis Diagnostics Market Attractiveness, by Product

    Figure 38: North America Hemostasis Diagnostics Market Attractiveness, by Test Type

    Figure 39: North America Hemostasis Diagnostics Market Attractiveness, by End-user

    Figure 40: Europe Hemostasis Diagnostics Market Size (US$ Mn) Forecast, 2019-2027

    Figure 41: Europe Hemostasis Diagnostics Market Attractiveness Analysis, by Country

    Figure 42: Europe Hemostasis Diagnostics Market Value Share Analysis, by Product, 2018 and 2027

    Figure 43: Europe Hemostasis Diagnostics Market Value Share Analysis, by Test Type, 2018 and 2027

    Figure 44: Europe Hemostasis Diagnostics Market Value Share Analysis, by End-user, 2018 and 2027

    Figure 45: Europe Hemostasis Diagnostics Market Value Share Analysis, by Country, 2018 and 2027

    Figure 46: Europe Hemostasis Diagnostics Market Attractiveness Analysis, by Product

    Figure 47: Europe Hemostasis Diagnostics Market Attractiveness Analysis, by Test Type

    Figure 48: Europe Hemostasis Diagnostics Market Attractiveness Analysis, by End-user

    Figure 49: Asia Pacific Hemostasis Diagnostics Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2027

    Figure 50: Asia Pacific Hemostasis Diagnostics Market Attractiveness Analysis, by Country 2019-2027

    Figure 51: Asia Pacific Hemostasis Diagnostics Market Value Share Analysis, by Product, 2018 and 2027

    Figure 52: Asia Pacific Hemostasis Diagnostics Market Value Share Analysis, by Test Type, 2018 and 2027

    Figure 53: Asia Pacific Hemostasis Diagnostics Market Value Share Analysis, by End-user, 2018 and 2027

    Figure 54: Asia Pacific Hemostasis Diagnostics Market Value Share Analysis, by Country, 2018 and 2027

    Figure 55: Asia Pacific Hemostasis Diagnostics Market Attractiveness Analysis, by Product

    Figure 56: Asia Pacific Hemostasis Diagnostics Market Attractiveness Analysis, by Test Type

    Figure 57: Asia Pacific Hemostasis Diagnostics Market Attractiveness Analysis, by End-user

    Figure 58: Latin America Hemostasis Diagnostics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027

    Figure 59: Latin America Hemostasis Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2019-2027

    Figure 60: Latin America Hemostasis Diagnostics Market Value Share Analysis, by Product, 2018 and 2027

    Figure 61: Latin America Hemostasis Diagnostics Market Value Share Analysis, by Test Type, 2018 and 2027

    Figure 62: Latin America Hemostasis Diagnostics Market Value Share Analysis, by End-user, 2018 and 2027

    Figure 63: Latin America Hemostasis Diagnostics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 64: Latin America Hemostasis Diagnostics Market Attractiveness Analysis, by Product

    Figure 65: Latin America Hemostasis Diagnostics Market Attractiveness Analysis, by Test Type

    Figure 66: Latin America Hemostasis Diagnostics Market Attractiveness Analysis, by End-user

    Figure 67: Middle East & Africa Hemostasis Diagnostics Market Size (US$ Mn) Forecast, 2017-2027

    Figure 68: Middle East & Africa Hemostasis Diagnostics Market Attractiveness Analysis, by Country/Sub-region

    Figure 69: Middle East & Africa Hemostasis Diagnostics Market Value Share Analysis, by Product, 2018 and 2027

    Figure 70: Middle East & Africa Hemostasis Diagnostics Market Value Share Analysis, by Test Type, 2018 and 2027

    Figure 71: Middle East & Africa Hemostasis Diagnostics Market Value Share Analysis, by End-user, 2018 and 2027

    Figure 72: Middle East & Africa Hemostasis Diagnostics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 73: Middle East & Africa Hemostasis Diagnostics Market Attractiveness Analysis, by Product

    Figure 74: Middle East & Africa Hemostasis Diagnostics Market Attractiveness Analysis, by Test Type

    Figure 75: Middle East & Africa Hemostasis Diagnostics Market Attractiveness Analysis, by End-user

    Figure 76: Global Hemostasis Diagnostics Market Share Analysis, by Company (2018)

Copyright © Transparency Market Research, Inc. All Rights reserved